New Zealand has higher mortality and hospital admission rates for asthma than England and Wales.
times higher in Auckland than in South
West Thames. The reported lifetime, 12 month, and one month prevalences of wheeze were also higher in Auckland (by 18 -5%, 32-1%, and 87-5%). Unexpectedly, the hospital admission rate for asthma in children of European descent aged [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] In this paper we compare admission and mortality data, information from prevalence surveys, data extracted from hospital case notes, and the approach of general practitioners to the care of acute and chronic childhood asthma between the Auckland Region of New Zealand and the South West Thames Health Region of England. We attempt to determine whether the differences in admission and mortality rates between these two countries are likely to be explained by differences in asthma morbidity, by differences in admission criteria, or by differences in the primary care of childhood asthma.
Methods

MORTALITY AND HOSPITAL ADMISSION DATA
For New Zealand (population 3 3 million) and for the Auckland Region (population 890 000) admission and mortality rates for asthma (ICD 493) month, and one month prevalences of wheeze are compared in table 8. All of these measures of prevalence were higher in Auckland, the greatest difference being in the prevalence of wheeze in the last month (+87-5%) and the least being in the lifetime prevalence (+ 18-5O'). why for Europeans Auckland has a higher mortality rate than South West Thames alongside a lower ratio of admissions to mortality, less than half of that in South West Thames (Auckland 207:1, South West Thames 539:1). The comparative data on asthma prevalence are of particular importance but need to be interpreted with caution. They are unlikely to be biased by age because the age distribution of the two groups was very similar. The questions used were also similar but not identical, and in Croydon the one month prevalence estimate was based on an interview rather than a questionnaire completed by parents as in Auckland. A more serious problem is that a period of seven years separated the surveys and if there had been an increase in the prevalence of asthma over time this might help to account for the differences observed. A recent review of prevalence surveys in the UK found little evidence for an increase in lifetime or 12 month period prevalence in the 20 years up to 1986.'" The patient simulation exercise also pointed to other important differences in asthma management by general practitioners. The most prominent difference in the management of the acute case was that more general practitioners in Auckland used adrenergic drugs and were more likely to give it by nebuliser. This was supplemented by an anticholinergic drug in 25%~of Auckland responses but in only 1 00 of those from London. There was no difference in the proportions of general practitioners using theophylline, corticosteroids, or any parenteral treatment. General practitioners in South West Thames tended overall to use other drugs, such as cromoglycate, antihistamines, theophylline suppositories, and antibiotics, more than general practitioners in Auckland. These drugs have no value in the acute episode. 25 We conclude that general practitioners in Auckland are using treatment for acute severe asthma that is at least as appropriate, if not more so, than that selected by their colleagues in South West Thames.
The management of chronic asthma by general practitioners, as shown by the second patient management problem, also showed substantial differences between the countries, especially in the investigations ordered and the choice of prophylactic asthma drugs used. The treatment proposed by the Auckland general practitioners tended to be more intensive. Between countries there was no difference in the interval before the follow up consultation or in general practitioners' attitudes to the participation of specialists in the management of chronic asthma.
We must emphasise that within both countries there were wide variations in the approach to both simulated cases. These variations were at least as great as the differences between countries and raise important questions concerning the effects of such variations on patient outcome and efficiency. The recently published international consensus statement on the management of asthma is therefore timely. 26 There is much interest in the types of adrenergic drugs in use in New Zealand as a result of the report that the use of fenoterol by metered dose inhaler is associated with an increased risk of death in severe asthma. 27 The present study is unable to compare the types of adrenergic drug used fully because both patient simulation scenarios state that the child is having salbutamol by metered dose inhaler at the time of presentation. Nevertheless, it is notable that in both cases a sizeable proportion of Auckland general practitioners changed to another type of adrenergic drug, predominantly fenoterol-in contrast to their British colleagues, who tended to continue with salbutamol.
We postulate, on the basis of this analysis, that the higher childhood asthma mortality in Auckland than in South West Thames is most likely be a result of the relatively higher level of morbidity which exists in Auckland. The quality of general practitioner care for asthma, as judged by simulation studies, was at least as good if not better in Auckland than in South West Thames. The possibility that the relatively greater willingness to manage asthma in the community might also contribute to the differences in mortality must also be considered.
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